Raymond James & Associates’s CVS Health CVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $128M | Sell |
2,041,004
-245,468
| -11% | -$14.3M | 0.08% | 213 |
|
|
2024
Q2 | $135M | Sell |
2,286,472
-372,541
| -14% | -$23.3M | 0.09% | 195 |
|
|
2024
Q1 | $212M | Sell |
2,659,013
-247,053
| -9% | -$18.9M | 0.14% | 123 |
|
|
2023
Q4 | $229M | Sell |
2,906,066
-15,478
| -0.5% | -$1.1M | 0.17% | 103 |
|
|
2023
Q3 | $204M | Sell |
2,921,544
-73,347
| -2% | -$5.2M | 0.17% | 106 |
|
|
2023
Q2 | $207M | Sell |
2,994,891
-4,257
| -0.1% | -$303K | 0.17% | 111 |
|
|
2023
Q1 | $223M | Sell |
2,999,148
-242,229
| -7% | -$20.3M | 0.19% | 97 |
|
|
2022
Q4 | $302M | Buy |
3,241,377
+80,844
| +3% | +$7.8M | 0.28% | 67 |
|
|
2022
Q3 | $301M | Sell |
3,160,533
-27,747
| -0.9% | -$2.75M | 0.3% | 60 |
|
|
2022
Q2 | $295M | Sell |
3,188,280
-86,448
| -3% | -$8.44M | 0.29% | 67 |
|
|
2022
Q1 | $331M | Sell |
3,274,728
-144,325
| -4% | -$15.2M | 0.28% | 66 |
|
|
2021
Q4 | $353M | Sell |
3,419,053
-42,634
| -1% | -$3.94M | 0.28% | 65 |
|
|
2021
Q3 | $294M | Buy |
3,461,687
+202,335
| +6% | +$16.9M | 0.26% | 69 |
|
|
2021
Q2 | $272M | Buy |
3,259,352
+101,212
| +3% | +$8.29M | 0.25% | 70 |
|
|
2021
Q1 | $238M | Buy |
3,158,140
+142,305
| +5% | +$10.4M | 0.24% | 75 |
|
|
2020
Q4 | $206M | Buy |
3,015,835
+102,585
| +4% | +$6.67M | 0.23% | 76 |
|
|
2020
Q3 | $170M | Sell |
2,913,250
-806,653
| -22% | -$50.2M | 0.21% | 80 |
|
|
2020
Q2 | $242M | Buy |
3,719,903
+238,898
| +7% | +$15M | 0.32% | 59 |
|
|
2020
Q1 | $207M | Sell |
3,481,005
-47,375
| -1% | -$3.16M | 0.33% | 55 |
|
|
2019
Q4 | $262M | Sell |
3,528,380
-80,301
| -2% | -$5.64M | 0.33% | 55 |
|
|
2019
Q3 | $228M | Buy |
3,608,681
+206,468
| +6% | +$12.2M | 0.32% | 55 |
|
|
2019
Q2 | $185M | Buy |
3,402,213
+560,358
| +20% | +$30.2M | 0.27% | 63 |
|
|
2019
Q1 | $153M | Buy |
2,841,855
+404,986
| +17% | +$25M | 0.23% | 79 |
|
|
2018
Q4 | $160M | Buy |
2,436,869
+146,125
| +6% | +$10.9M | 0.28% | 66 |
|
|
2018
Q3 | $180M | Buy |
2,290,744
+436,799
| +24% | +$31.2M | 0.28% | 62 |
|
|
2018
Q2 | $119M | Sell |
1,853,945
-125,857
| -6% | -$8.29M | 0.2% | 98 |
|
|
2018
Q1 | $123M | Buy |
1,979,802
+559,955
| +39% | +$40.2M | 0.22% | 88 |
|
|
2017
Q4 | $103M | Sell |
1,419,847
-146,560
| -9% | -$10.7M | 0.19% | 103 |
|
|
2017
Q3 | $127M | Buy |
1,566,407
+40,272
| +3% | +$3.19M | 0.26% | 78 |
|
|
2017
Q2 | $123M | Buy |
1,526,135
+76,368
| +5% | +$6.03M | 0.27% | 73 |
|
|
2017
Q1 | $114M | Buy |
1,449,767
+462,830
| +47% | +$36.9M | 0.26% | 77 |
|
|
2016
Q4 | $77.9M | Buy |
986,937
+48,555
| +5% | +$3.93M | 0.2% | 108 |
|
|
2016
Q3 | $83.5M | Sell |
938,382
-3,616
| -0.4% | -$341K | 0.23% | 94 |
|
|
2016
Q2 | $90.2M | Buy |
941,998
+56,319
| +6% | +$5.61M | 0.28% | 69 |
|
|
2016
Q1 | $91.9M | Buy |
885,679
+59,655
| +7% | +$5.8M | 0.31% | 59 |
|
|
2015
Q4 | $80.8M | Buy |
826,024
+56,588
| +7% | +$5.54M | 0.29% | 67 |
|
|
2015
Q3 | $74.2M | Buy |
769,436
+76,710
| +11% | +$8.06M | 0.3% | 61 |
|
|
2015
Q2 | $72.7M | Buy |
692,726
+123,075
| +22% | +$12.6M | 0.28% | 67 |
|
|
2015
Q1 | $58.8M | Buy |
569,651
+23,344
| +4% | +$2.36M | 0.26% | 79 |
|
|
2014
Q4 | $52.6M | Buy |
546,307
+83,284
| +18% | +$7.34M | 0.26% | 75 |
|
|
2014
Q3 | $36.9M | Buy |
463,023
+28,353
| +7% | +$2.24M | 0.21% | 83 |
|
|
2014
Q2 | $32.8M | Buy |
434,670
+14,392
| +3% | +$1.09M | 0.2% | 83 |
|
|
2014
Q1 | $31.5M | Sell |
420,278
-3,124
| -0.7% | -$221K | 0.22% | 75 |
|
|
2013
Q4 | $30.3M | Buy |
423,402
+73,917
| +21% | +$4.75M | 0.23% | 75 |
|
|
2013
Q3 | $19.8M | Buy |
349,485
+24,570
| +8% | +$1.46M | 0.17% | 113 |
|
|
2013
Q2 | $18.6M | Buy |
+324,915
| New | +$18.8M | 0.18% | 113 |
|
Other funds holding CVS
Raymond James & Associates's CVS Position: Q3 2024 in Review
Raymond James & Associates reduced its CVS Health (CVS) stake by 11% in Q3 2024, selling an estimated $14.3M and leaving 2,041,004 shares worth $128M. The position accounts for 0.08% of the portfolio, ranked #213.
Raymond James & Associates first reported a position in CVS in Q2 2013 and has held it in 46 quarters since. The position peaked at $353M in Q4 2021. 1,841 funds tracked by Wall St. Rank hold CVS as of Q3 2024.
- Raymond James & Associates held 2,041,004 shares of CVS Health worth $128M as of Q3 2024.
- Raymond James & Associates sold 245,468 CVS Health shares in Q3 2024, an estimated $14.3M.
- CVS Health made up 0.08% of Raymond James & Associates's portfolio in Q3 2024, its #213 holding.
- Raymond James & Associates first reported a position in CVS Health in Q2 2013 and has held it in 46 quarters since.
- Raymond James & Associates's CVS Health position peaked at $353M in Q4 2021.
- 1,841 funds tracked by Wall St. Rank held CVS Health as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.